T2 Biosystems Inc. (NASDAQ:TTOO) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $4.92 and last traded at $5.03, with a volume of 83,870 shares traded. The stock had previously closed at $5.11.

Several research analysts have recently issued reports on the company. Leerink Swann reissued a “buy” rating on shares of T2 Biosystems in a research report on Monday, May 2nd. Janney Montgomery Scott reissued a “hold” rating on shares of T2 Biosystems in a research report on Saturday, July 9th. Cantor Fitzgerald reissued a “buy” rating on shares of T2 Biosystems in a research report on Saturday, July 9th. Morgan Stanley reissued a “hold” rating on shares of T2 Biosystems in a research report on Monday, May 2nd. Finally, Canaccord Genuity reissued a “buy” rating on shares of T2 Biosystems in a research report on Sunday, May 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $10.90.

The firm’s market cap is $124.33 million. The company’s 50 day moving average is $7.98 and its 200 day moving average is $8.78.

T2 Biosystems (NASDAQ:TTOO) last announced its earnings results on Monday, May 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.01. The business earned $1.10 million during the quarter. The firm’s revenue for the quarter was up 485.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.53) earnings per share. Analysts anticipate that T2 Biosystems Inc. will post ($2.17) earnings per share for the current year.

In other T2 Biosystems news, SVP Rahul Dhanda sold 3,589 shares of the business’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $8.16, for a total transaction of $29,286.24. Following the completion of the transaction, the senior vice president now owns 3,589 shares in the company, valued at $29,286.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in T2 Biosystems stock. Aisling Capital LLC raised its position in T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems comprises 5.3% of Aisling Capital LLC’s portfolio, making the stock its 6th largest position. Aisling Capital LLC owned approximately 13.89% of T2 Biosystems worth $30,971,000 as of its most recent filing with the SEC.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.